高血清PCSK9与肾移植受者移植后新发糖尿病风险增加相关
在453例非糖尿病肾移植受者中,前瞻性测定血清PCSK9水平并随访中位10年。PCSK9最高三分位组新发糖尿病发生率为23%,高于最低两分位组的12%(P<0.001);PCSK9每增加1个标准差,新发糖尿病风险比为1.34(95%CI 1.10-1.63,P=0.004)。PCSK9与全因死亡、心血管死亡或移植物失败无关。
要点
- PCSK9最高三分位组新发糖尿病发生率为23%,最低两分位组为12%(P<0.001)。
- PCSK9每增加1个标准差,新发糖尿病风险比为1.34(95%CI 1.10-1.63,P=0.004)。
- PCSK9与全因死亡、心血管死亡或移植物失败无显著关联。
核心结论
- 循环PCSK9与肾移植受者新发糖尿病相关;PCSK9通路可能参与新发糖尿病的发病机制。
研究设计与样本
- 在大学附属医院环境中,2001年至2003年招募的肾功能稳定至少1年的非糖尿病肾移植受者。
- 共纳入453例肾移植受者,年龄51±12岁,56%为男性,移植后6.1(2.7-11.7)年。
- 血清PCSK9采用酶联免疫吸附法测定。
- 采用Cox比例风险分析评估PCSK9与新发糖尿病、全因死亡、心血管死亡和移植物失败的关联。
主要发现
- 血清PCSK9为107.1±43.4 μg/L。
- 中位随访10年期间,70例发生新发糖尿病,123例死亡,59例发生移植物失败。
- 新发糖尿病在PCSK9最高三分位组发生率为23%,在最低两分位组为12%(P<0.001)。
- 在粗Cox回归分析中,PCSK9每增加1个标准差与新发糖尿病显著相关,风险比为1.34(95%CI 1.10-1.63,P=0.004)。
- 该关联在调整包括他汀类药物使用在内的潜在混杂因素后仍独立存在。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: New-onset diabetes after transplantation (NODAT) is a major complication in renal transplant recipients (RTRs). Cholesterol metabolism has been linked to diabetes development. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is crucial in LDL receptor regulation. Its association with NODAT is unknown. We prospectively determined the association between serum PCSK9 levels and NODAT development and then with all-cause mortality, cardiovascular mortality, and renal graft failure. RESEARCH DESIGN AND METHODS: In a university setting, nondiabetic RTRs recruited between 2001 and 2003 with a functional graft for ≥1 year were eligible. Serum PCSK9 was measured by ELISA. Cox proportional hazards analysis was used to assess the association of PCSK9 with the development of NODAT, all-cause mortality, cardiovascular mortality, and graft failure. RESULTS: In 453 RTRs (age 51 ± 12 years, 56% male; 6.1 [2.7-11.7] years after transplantation), serum PCSK9 was 107.1 ± 43.4 μg/L. During a median follow-up of 10 years, 70 RTRs developed NODAT, 123 died, and 59 developed graft failure. NODAT occurred more frequently in the upper PCSK9 tertile (23%) versus the lowest two PCSK9 tertiles (12%; P < 0.001). In crude Cox regression analyses, PCSK9 was significantly associated with development of NODAT (hazard ratio 1.34 [95% CI 1.10-1.63]) per SD change (P = 0.004). This association remained independent of adjustment for potential confounders, including statin use. PCSK9 was not associated with all-cause mortality, cardiovascular mortality, or graft failure. CONCLUSIONS: Circulating PCSK9 is associated with NODAT in RTRs. The PCSK9 pathway may contribute to the pathogenesis of NODAT.
引用
- Eisenga MF, Zelle DM, Sloan JH, et al. High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients. Diabetes Care. 2017. PMID: 28461454. doi:10.2337/dc16-2258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。